VIDEO: Microbiome-based biotherapeutic effective in real-world C. difficile population
Click Here to Manage Email Alerts
LAS VEGAS — In this video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discussed a study assessing the investigational live microbiota-based biotherapeutic, RBX2660 for the treatment of Clostridioides difficile, at the ACG Annual Scientific Meeting.
Feuerstadt, assistant clinical professor of Medicine at Yale University, and colleagues enrolled 94 patients with recurrent C. difficile who received RBX2660 (Ferring Pharmaceuticals/Rebiotix) rectally.
The efficacy of RBX2660 among these patients was 70.2%. No concerning signals were noted regarding safety.
“RBX2660 is an effective and safe therapy, both within clinical trials but also in a real-world population,” he said.
Editors note: The title has been updated to reflect a more precise depiction of the story.
Collapse
Feuerstadt P, et al. Poster: P2217. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Read more about
Click Here to Manage Email Alerts